phv00122908.v1  	  Meds: Acetaminophen 	 meds  acetaminophen 	 NULL 	 NULL 	 NULL 	 NULL 	 acetaminophen 	 C0000970 	 orch,phsu 	 study subject 	 C0681850 	 grup	Medication Patient
phv00123181.v1  	  74 On average, how many tablets acetaminophen taken 	 74 on average, how many tablets acetaminophen taken 	 NULL 	 NULL 	 NULL 	 NULL 	 acetaminophen 	 C0000970 	 orch,phsu 	 study subject 	 C0681850 	 grup	Medication Patient
phv00086503.v2  	  ACETYLCHOLINE ESTERASE INHIBITORS FOR ALZH'S 	 acetylcholine esterase inhibitors for alzh s 	 NULL 	 NULL 	 NULL 	 NULL 	 acetylcholine;esterase inhibitor;acetylcholine measurement 	 C0001041;C0596537;C0523441 	 nsba,orch,phsu;phsu;lbpr 	 study subject 	 C0681850 	 grup	Medication Patient;Lab Tests Patient
phv00110634.v1  	  Acetylcholine esterase inhibitors for Al 	 acetylcholine esterase inhibitors for attatchment loss 	 NULL 	 NULL 	 NULL 	 NULL 	 acetylcholine;esterase inhibitor;acetylcholine measurement 	 C0001041;C0596537;C0523441 	 nsba,orch,phsu;phsu;lbpr 	 study subject 	 C0681850 	 grup	Medication Patient;Lab Tests Patient
phv00007292.v1  	  BETA BLOCKER GROUP 	 beta blocker group 	 NULL 	 NULL 	 NULL 	 NULL 	 adrenergic beta-antagonists 	 C0001645 	 phsu 	 study subject 	 C0681850 	 grup	Medication Patient
phv00105031.v1  	  Beta-blockers with diuretics 	 beta blockers with diuretics 	 NULL 	 NULL 	 NULL 	 NULL 	 adrenergic beta-antagonists;diuretics 	 C0001645;C0012798 	 phsu;phsu 	 study subject 	 C0681850 	 grup	Medication Patient
phv00086924.v2  	  BETA-BLOCKERS WITH DIURETICS 	 beta blockers with diuretics 	 NULL 	 NULL 	 NULL 	 NULL 	 adrenergic beta-antagonists;diuretics 	 C0001645;C0012798 	 phsu;phsu 	 study subject 	 C0681850 	 grup	Medication Patient
phv00053894.v2  	  YEARS TAKING ALLOPURINOL (ALL PARTICIPANTS) 	 years taking allopurinol  all participants 	 NULL 	 NULL 	 NULL 	 NULL 	 allopurinol 	 C0002144 	 orch,phsu 	 participant 	 C0679646 	 popg	Medication Patient
phv00099575.v1  	  Combinations of angiotensin II antagonists 	 combinations of angiotensin ii antagonists 	 NULL 	 NULL 	 NULL 	 NULL 	 angiotensin ii 	 C0003009 	 aapp,bacs,phsu 	 study subject 	 C0681850 	 grup	Medication Patient
phv00086002.v2  	  ACE INHIBITORS WITH DIURETICS 	 angiotensin converting enzyme inhibitors with diuretics 	 NULL 	 NULL 	 NULL 	 NULL 	 angiotensin-converting enzyme inhibitors;diuretics 	 C0003015;C0012798 	 phsu;phsu 	 study subject 	 C0681850 	 grup	Medication Patient
phv00106435.v1  	  ACE Inhibitors without diuretics 	 angiotensin converting enzyme inhibitors without diuretics 	 NULL 	 NULL 	 NULL 	 NULL 	 angiotensin-converting enzyme inhibitors;diuretics 	 C0003015;C0012798 	 phsu;phsu 	 study subject 	 C0681850 	 grup	Medication Patient
phv00009191.v3  	  RENIN-ANGIOTENSIN BLOCKING DRUGS 	 renin angiotensin blocking drugs 	 NULL 	 NULL 	 NULL 	 NULL 	 angiotensins;chymosin 	 C0003018;C0035100 	 aapp,bacs,phsu;aapp,enzy,phsu 	 study subject 	 C0681850 	 grup	Medication Patient
phv00083093.v1  	  ANTI-ARRHYTHMICS, CLASS 1C 	 anti arrhythmics, class1 c 	 NULL 	 NULL 	 NULL 	 NULL 	 anti-arrhythmia agents 	 C0003195 	 phsu 	 study subject 	 C0681850 	 grup	Medication Patient
phv00103076.v1  	  Anti-arrhythmics, class 1C 	 anti arrhythmics, class1 c 	 NULL 	 NULL 	 NULL 	 NULL 	 anti-arrhythmia agents 	 C0003195 	 phsu 	 study subject 	 C0681850 	 grup	Medication Patient
phv00056974.v1  	  Non-steroidal anti-inflammatory agents, excluding aspirin 	 non steroidal anti inflammatory agents, excluding aspirin 	 NULL 	 NULL 	 NULL 	 NULL 	 anti-inflammatory agents, non-steroidal;aspirin 	 C0003211;C0004057 	 phsu;orch,phsu 	 study subject 	 C0681850 	 grup	Medication Patient
phv00107426.v1  	  Tricyclic anti-depressants 	 tricyclic anti depressants 	 NULL 	 NULL 	 NULL 	 NULL 	 tricyclic antidepressive agents 	 C0003290 	 phsu 	 study subject 	 C0681850 	 grup	Medication Patient
phv00173653.v1  	  Antineoplastic agents that have been prescribed to the patient 	 antineoplastic agents that have been prescribed to the patient 	 NULL 	 NULL 	 NULL 	 NULL 	 antineoplastic agents;prescribed 	 C0003392;C0278329 	 orch,phsu;hlca 	 study subject 	 C0681850 	 grup	Medication Patient
phv00127076.v1  	  SFFQ: arginine (gm) 	 sffq  arginine  gm 	 NULL 	 NULL 	 NULL 	 NULL 	 arginine 	 C0003765 	 aapp,bacs,phsu 	 study subject 	 C0681850 	 grup	Medication Patient
phv00054305.v2  	  OTHER REGULAR-STRENGTH ASPIRIN NAME (ALL PARTICIPANTS) 	 other regular strength aspirin name  all participants 	 NULL 	 NULL 	 NULL 	 NULL 	 aspirin 	 C0004057 	 orch,phsu 	 participant 	 C0679646 	 popg	Medication Patient
phv00127944.v1  	  33: Now taking aspirin? 	 33  now taking aspirin 	 NULL 	 NULL 	 NULL 	 NULL 	 aspirin 	 C0004057 	 orch,phsu 	 study subject 	 C0681850 	 grup	Medication Patient
phv00056788.v1  	  Aspirin:  the last two weeks, did you take any aspirin or aspirin-containing medicines such as Bufferin, Anacin, or Ascriptin 	 aspirin  the last two weeks, did you take any aspirin or aspirin containing medicines such as bufferin, anacin, or ascriptin 	 NULL 	 NULL 	 NULL 	 NULL 	 aspirin;pharmaceutical preparations;bufferin;anacin;ascriptin 	 C0004057;C0013227;C0719034;C0718504;C0052479 	 orch,phsu;phsu;orch,phsu;orch,phsu;orch,phsu 	 study subject 	 C0681850 	 grup	Medication Patient
phv00034122.v1  	  Average number of aspirin or other prostaglandin inhibitors - containing tablets per month 	 average number of aspirin or other prostaglandin inhibitors containing tablets per month 	 NULL 	 NULL 	 NULL 	 NULL 	 aspirin;prostaglandin antagonists 	 C0004057;C0033529 	 orch,phsu;phsu 	 study subject 	 C0681850 	 grup	Medication Patient
phv00086003.v2  	  ASPIRIN FROM 280804 (ANTI-INFLAM AGENTS) 	 aspirin from 280804   anti inflam agents 	 NULL 	 NULL 	 NULL 	 NULL 	 aspirin;anti-anxiety agents 	 C0004057;C0040616 	 orch,phsu;phsu 	 study subject 	 C0681850 	 grup	Medication Patient
phv00006877.v1  	  ASPIRIN: USUAL ASPIRIN DOSE 	 aspirin  usual aspirin dose 	 NULL 	 NULL 	 NULL 	 NULL 	 aspirin;dose number:number:point in time:^patient:quantitative 	 C0004057;C1114758 	 orch,phsu;clna 	 study subject 	 C0681850 	 grup	Medication Patient
phv00010183.v3  	  ASPIRIN: USUAL ASPIRIN DOSE FOR ABOVE 	 aspirin  usual aspirin dose for above 	 NULL 	 NULL 	 NULL 	 NULL 	 aspirin;dose number:number:point in time:^patient:quantitative 	 C0004057;C1114758 	 orch,phsu;clna 	 study subject 	 C0681850 	 grup	Medication Patient
phv00015058.v1  	  E6. Benzodiazepines Restoril, (Participants with European ancestry). DIGS3 	 e6  benzodiazepines restoril,  participants with european ancestry   digs3 	 Ethnicity 	 ethnic european 	 C0239307 	 popg 	 benzodiazepines;restoril 	 C0005064;C0723045 	 orch,phsu;orch,phsu 	 participant 	 C0679646 	 popg	Demographics Patient;Medication Patient
phv00127086.v1  	  SFFQ: caffeine (mg) 	 sffq  caffeine  magnesium 	 NULL 	 NULL 	 NULL 	 NULL 	 caffeine 	 C0006644 	 orch,phsu 	 study subject 	 C0681850 	 grup	Medication Patient
phv00095443.v1  	  Caffeine (mg) 	 caffeine  magnesium 	 NULL 	 NULL 	 NULL 	 NULL 	 caffeine 	 C0006644 	 orch,phsu 	 study subject 	 C0681850 	 grup	Medication Patient
phv00007288.v1  	  CALCIUM CHANNEL BLOCKER GROUP 	 calcium channel blocker group 	 NULL 	 NULL 	 NULL 	 NULL 	 calcium channel blockers 	 C0006684 	 phsu 	 study subject 	 C0681850 	 grup	Medication Patient
phv00009178.v3  	  CALCIUM CHANNEL BLOCKERS 	 calcium channel blockers 	 NULL 	 NULL 	 NULL 	 NULL 	 calcium channel blockers 	 C0006684 	 phsu 	 study subject 	 C0681850 	 grup	Medication Patient
phv00106457.v1  	  T-type calcium-channel blocker 	 ttype calcium channel blocker 	 NULL 	 NULL 	 NULL 	 NULL 	 calcium channel blockers 	 C0006684 	 phsu 	 study subject 	 C0681850 	 grup	Medication Patient
phv00086950.v2  	  IMMEDIATE-RELEASE CCBS = NIFIR OR DIHIR OR VERIR OR DLTIR 	 immediate release calcium channel blockers = nifir or type of medication or verir or type of mediation-dltir  immediate-release diltiazem 	 NULL 	 NULL 	 NULL 	 NULL 	 calcium channel blockers;pharmaceutical preparations;diltiazem 	 C0006684;C0013227;C0012373 	 phsu;phsu;orch,phsu 	 study subject 	 C0681850 	 grup	Medication Patient
phv00008780.v3  	  CARDIAC GLYCOSIDES 	 cardiac glycosides 	 NULL 	 NULL 	 NULL 	 NULL 	 cardiac glycosides 	 C0007158 	 carb,phsu 	 study subject 	 C0681850 	 grup	Medication Patient
phv00008779.v3  	  ANY CARDIOVASCULAR MEDICATIONS? 	 any cardiovascular medications 	 NULL 	 NULL 	 NULL 	 NULL 	 cardiovascular agents 	 C0007220 	 phsu 	 study subject 	 C0681850 	 grup	Medication Patient
phv00006466.v1  	  CARDIOVASCULAR MEDICATIONS - BETA BLOCKERS (SPECIFY) 	 cardiovascular medications beta blockers  specify 	 NULL 	 NULL 	 NULL 	 NULL 	 cardiovascular agents;adrenergic beta-antagonists 	 C0007220;C0001645 	 phsu;phsu 	 study subject 	 C0681850 	 grup	Medication Patient
phv00010176.v3  	  CARDIOVASCULAR MEDICATIONS: ANTI-ARRHYTHMICS (QUINIDINE, PROCAINAMIDE, AMIODARONE, SOTALOL DISOPYRAMIDE, ETC.) 	 cardiovascular medications  anti arrhythmics  quinidine, procainamide, amiodarone, sotalol disopyramide, etc 	 NULL 	 NULL 	 NULL 	 NULL 	 cardiovascular agents;anti-arrhythmia agents;quinidine;procainamide;amiodarone;sotalol;disopyramide 	 C0007220;C0003195;C0034414;C0033216;C0002598;C0037707;C0012702 	 phsu;phsu;orch,phsu;orch,phsu;orch,phsu;orch,phsu;orch,phsu 	 study subject 	 C0681850 	 grup	Medication Patient
phv00007287.v1  	  CARDIOVASCULAR MEDICATIONS: CALCIUM CHANNEL BLOCKERS 	 cardiovascular medications  calcium channel blockers 	 NULL 	 NULL 	 NULL 	 NULL 	 cardiovascular agents;calcium channel blockers 	 C0007220;C0006684 	 phsu;phsu 	 study subject 	 C0681850 	 grup	Medication Patient
phv00010172.v3  	  CARDIOVASCULAR MEDICATIONS: RENIN-ANGIOTENSIN BLOCKING DRUGS (ACE) (CAPTOPRIL, ENALAPRIL, LISINOPRIL) 	 cardiovascular medications  renin angiotensin blocking drugs  angiotensin converting enzyme   captopril, enalapril, lisinopril 	 NULL 	 NULL 	 NULL 	 NULL 	 cardiovascular agents;captopril;chymosin;enalapril;lisinopril 	 C0007220;C0006938;C0035100;C0014025;C0065374 	 phsu;aapp,phsu;aapp,enzy,phsu;aapp,phsu;aapp,phsu 	 study subject 	 C0681850 	 grup	Medication Patient
phv00010187.v3  	  NON-CARDIOVASCULAR MEDICATIONS: ANTI-CHOLESTEROL DRUGS (STATINS - E.G. LOVASTATIN, PRAVASTATIN) 	 non cardiovascular medications  anti cholesterol drugs  statins e gram  lovastatin, pravastatin 	 NULL 	 NULL 	 NULL 	 NULL 	 cardiovascular agents;pharmaceutical preparations;serum total cholesterol measurement;medications:presence or identity:duration of the study:^patient:nominal;medications:-:point in time:^patient:-;hydroxymethylglutaryl-coa reductase inhibitors;lovastatin;pravastatin 	 C0007220;C0013227;C1445957;C0802604;C2598133;C0360714;C0024027;C0085542 	 phsu;phsu;lbpr;clna;clna;orch,phsu;orch,phsu;orch,phsu 	 study subject 	 C0681850 	 grup	Medication Patient;Lab Tests Patient
phv00173730.v1  	  Cardiovascular agents that have been prescribed to the patient 	 cardiovascular agents that have been prescribed to the patient 	 NULL 	 NULL 	 NULL 	 NULL 	 cardiovascular agents;prescribed 	 C0007220;C0278329 	 phsu;hlca 	 study subject 	 C0681850 	 grup	Medication Patient
phv00007304.v1  	  CARDIOVASCULAR MEDICATIONS: PERIPHERAL VASODILATORS (HYDRALAZINE, MINOXIDIL, ETC) 	 cardiovascular medications  peripheral vasodilators  hydralazine, minoxidil, etc 	 NULL 	 NULL 	 NULL 	 NULL 	 cardiovascular agents;peripheral vasodilators;hydralazine;minoxidil 	 C0007220;C0724804;C0020223;C0026196 	 phsu;phsu;orch,phsu;orch,phsu 	 study subject 	 C0681850 	 grup	Medication Patient
phv00006869.v1  	  CARDIOVASCULAR MEDICATIONS: OTHER ANTI-HYPERTENSIVES 	 cardiovascular medications  other anti hypertensives 	 NULL 	 NULL 	 NULL 	 NULL 	 cardiovascular agents;others;antihypertensive agents 	 C0007220;C1955473;C0003364 	 phsu;fndg;phsu 	 study subject 	 C0681850 	 grup	Medication Patient
phv00018477.v1  	  J49. Cocaine.  (Participants with European ancestry). DIGS4 	 j49   cocaine   participants with european ancestry   diagnostic interview for genetic studies 	 Ethnicity 	 ethnic european 	 C0239307 	 popg 	 cocaine;cocaine measurement;diagnosis;genetic study 	 C0009170;C0202362;C0011900;C2827447 	 hops,orch,phsu;lbpr;fndg;resa 	 participant 	 C0679646 	 popg	Demographics Patient;Medication Patient;Lab Tests Patient;Substance Use History;Research Attributes
phv00018401.v1  	  J37. Cocaine.  (Participants with European ancestry). DIGS4 	 j37   cocaine   participants with european ancestry   diagnostic interview for genetic studies 	 Ethnicity 	 ethnic european 	 C0239307 	 popg 	 cocaine;cocaine measurement;diagnosis;genetic study 	 C0009170;C0202362;C0011900;C2827447 	 hops,orch,phsu;lbpr;fndg;resa 	 participant 	 C0679646 	 popg	Demographics Patient;Medication Patient;Lab Tests Patient;Substance Use History;Research Attributes
phv00016040.v1  	  J51. Cocaine High in Sch/Work, (Participants with European ancestry). DIGS3 	 j51   cocaine high in sch work,  participants with european ancestry   digs3 	 Ethnicity 	 ethnic european 	 C0239307 	 popg 	 cocaine;cocaine measurement;spindle cell hemangioma 	 C0009170;C0202362;C1304508 	 hops,orch,phsu;lbpr;neop 	 participant 	 C0679646 	 popg	Demographics Patient;Medication Patient;Lab Tests Patient;Substance Use History;Medical History
phv00065683.v1  	  F3. Diabetes management: units Ultralente insulin used - other 	 f3  diabetes management  units ultralente insulin used other 	 NULL 	 NULL 	 NULL 	 NULL 	 diabetes;ultralente insulin;disease management;diabetes mellitus;used by 	 C0011847;C0041616;C0376636;C0011849;C1273517 	 dsyn;aapp,horm,phsu;hlca;dsyn;fndg 	 study subject 	 C0681850 	 grup	Medication Patient;Medical History
phv00048670.v1  	  F3. Diabetes management: units NPH insulin used-supper 	 f3  diabetes management  units neutral protamine hagedor insulin used supper 	 NULL 	 NULL 	 NULL 	 NULL 	 diabetes;insulin, neutral;protamines;disease management;diabetes mellitus;used by 	 C0011847;C0063657;C0033603;C0376636;C0011849;C1273517 	 dsyn;aapp,phsu;aapp,bacs,phsu;hlca;dsyn;fndg 	 study subject 	 C0681850 	 grup	Medication Patient;Medical History
phv00048962.v1  	  F4. Diabetes management: total number of units/day of insulin 	 f4  diabetes management  total number of units day of insulin 	 NULL 	 NULL 	 NULL 	 NULL 	 diabetes;disease management;diabetes mellitus;insulin;recombinant insulin 	 C0011847;C0376636;C0011849;C0021641;C1533581 	 dsyn;hlca;dsyn;aapp,horm,phsu;aapp,horm,phsu 	 study subject 	 C0681850 	 grup	Medication Patient;Medical History
phv00169156.v2  	  Heroin Use 	 heroin use 	 NULL 	 NULL 	 NULL 	 NULL 	 heroin 	 C0011892 	 hops,orch,phsu 	 study subject 	 C0681850 	 grup	Medication Patient;Substance Use History
phv00156479.v2  	  Dietary Phenylalanine (g) 	 dietary phenylalanine  gram 	 NULL 	 NULL 	 NULL 	 NULL 	 diet;phenylalanine 	 C0012155;C0031453 	 food;aapp,bacs,phsu 	 study subject 	 C0681850 	 grup	Medication Patient;Eating or Nutritional Finding
phv00156483.v2  	  Dietary Tryptophan (g) 	 dietary tryptophan  gram 	 NULL 	 NULL 	 NULL 	 NULL 	 diet;tryptophan 	 C0012155;C0041249 	 food;aapp,bacs,phsu 	 study subject 	 C0681850 	 grup	Medication Patient;Eating or Nutritional Finding
phv00108248.v1  	  Immediate-release diltiazem 	 immediate release diltiazem 	 NULL 	 NULL 	 NULL 	 NULL 	 diltiazem 	 C0012373 	 orch,phsu 	 study subject 	 C0681850 	 grup	Medication Patient
phv00104462.v1  	  Any diuretic 	 any diuretic 	 NULL 	 NULL 	 NULL 	 NULL 	 diuretics 	 C0012798 	 phsu 	 study subject 	 C0681850 	 grup	Medication Patient
phv00086931.v2  	  ANY DIURETIC 	 any diuretic 	 NULL 	 NULL 	 NULL 	 NULL 	 diuretics 	 C0012798 	 phsu 	 study subject 	 C0681850 	 grup	Medication Patient
phv00095245.v1  	  MEDICATION CODE NO. -- REPLACES Q7C 	 medication code no  replaces q7 c 	 NULL 	 NULL 	 NULL 	 NULL 	 pharmaceutical preparations 	 C0013227 	 phsu 	 study subject 	 C0681850 	 grup	Medication Patient
phv00083806.v2  	  NAME OF 3RD MEDICATION 	 name of 3rd medication 	 NULL 	 NULL 	 NULL 	 NULL 	 pharmaceutical preparations 	 C0013227 	 phsu 	 study subject 	 C0681850 	 grup	Medication Patient
phv00095290.v1  	  TAKE MEDICATION L IN PAST 24 HRS? Q15D 	 take medication l in past 24 hours  q15 d 	 NULL 	 NULL 	 NULL 	 NULL 	 pharmaceutical preparations 	 C0013227 	 phsu 	 study subject 	 C0681850 	 grup	Medication Patient
phv00102833.v1  	  STOP ANY MEDICATION IN PAST MONTH 	 stop any medication in past month 	 NULL 	 NULL 	 NULL 	 NULL 	 pharmaceutical preparations 	 C0013227 	 phsu 	 study subject 	 C0681850 	 grup	Medication Patient
phv00095224.v1  	  MEDICATION CODE NO. -- REPLACES Q04B 	 medication code no  replaces q04 b 	 NULL 	 NULL 	 NULL 	 NULL 	 pharmaceutical preparations 	 C0013227 	 phsu 	 study subject 	 C0681850 	 grup	Medication Patient
phv00114475.v2  	  MEDICATION NUMBER. Q 4.03A 	 medication number  q4 03 a 	 NULL 	 NULL 	 NULL 	 NULL 	 pharmaceutical preparations 	 C0013227 	 phsu 	 study subject 	 C0681850 	 grup	Medication Patient
phv00095109.v1  	  TAKE MEDICATION K IN PAST 24 HRS? Q14D 	 take medication k in past 24 hours  q14 d 	 NULL 	 NULL 	 NULL 	 NULL 	 pharmaceutical preparations 	 C0013227 	 phsu 	 study subject 	 C0681850 	 grup	Medication Patient
phv00104463.v1  	  Any lipid-lowering medication 	 any lipid lowering medication 	 NULL 	 NULL 	 NULL 	 NULL 	 pharmaceutical preparations 	 C0013227 	 phsu 	 study subject 	 C0681850 	 grup	Medication Patient
phv00105635.v1  	  DAYS TOOK THIS MEDICINE IN LAST TWO WEEK 	 days took this medicine in last two week 	 NULL 	 NULL 	 NULL 	 NULL 	 pharmaceutical preparations 	 C0013227 	 phsu 	 study subject 	 C0681850 	 grup	Medication Patient
phv00118693.v2  	  MEDICATION NUMBER: HORMONE MED 	 medication number  hormone med 	 NULL 	 NULL 	 NULL 	 NULL 	 pharmaceutical preparations 	 C0013227 	 phsu 	 study subject 	 C0681850 	 grup	Medication Patient
phv00108767.v1  	  STOP ANY MEDICATION IN PAST MONTH 	 stop any medication in past month 	 NULL 	 NULL 	 NULL 	 NULL 	 pharmaceutical preparations 	 C0013227 	 phsu 	 study subject 	 C0681850 	 grup	Medication Patient
phv00065927.v1  	  P12a. Medication, grade of right femoral pulse 	 p12 a  medication, grade of right femoral pulse 	 NULL 	 NULL 	 NULL 	 NULL 	 pharmaceutical preparations 	 C0013227 	 phsu 	 study subject 	 C0681850 	 grup	Medication Patient;Clinical Attributes
phv00015714.v1  	  I 30. ETOH+Drugs Dangerous Mix, (Participants with European ancestry). DIGS3 	 i 30  etoh+drugs dangerous mix,  participants with european ancestry   digs3 	 Ethnicity 	 ethnic european 	 C0239307 	 popg 	 pharmaceutical preparations 	 C0013227 	 phsu 	 participant 	 C0679646 	 popg	Demographics Patient;Medication Patient
phv00108147.v1  	  NAME OF FIRST MEDICATION CHANGED 	 name of first medication changed 	 NULL 	 NULL 	 NULL 	 NULL 	 pharmaceutical preparations 	 C0013227 	 phsu 	 study subject 	 C0681850 	 grup	Medication Patient
phv00158561.v1  	  Medication ongoing - coded fields 	 medication ongoing coded fields 	 NULL 	 NULL 	 NULL 	 NULL 	 pharmaceutical preparations 	 C0013227 	 phsu 	 study subject 	 C0681850 	 grup	Medication Patient
phv00053417.v1  	  B6 Medication (row 25), (African American participants). DIGS4 	 b6 medication  row 25 ,  african american participants   diagnostic interview for genetic studies 	 Race 	 african american 	 C0085756 	 popg 	 pharmaceutical preparations;diagnosis;genetic study 	 C0013227;C0011900;C2827447 	 phsu;fndg;resa 	 participant 	 C0679646 	 popg	Demographics Patient;Medication Patient;Research Attributes
phv00019156.v1  	  Q11.  Use of pills, drugs.  (Participants with European ancestry). DIGS4 	 q11   use of pills, drugs   participants with european ancestry   diagnostic interview for genetic studies 	 Ethnicity 	 ethnic european 	 C0239307 	 popg 	 pharmaceutical preparations;diagnosis;genetic study 	 C0013227;C0011900;C2827447 	 phsu;fndg;resa 	 participant 	 C0679646 	 popg	Demographics Patient;Medication Patient;Research Attributes
phv00095158.v1  	  MEDICATION CODE (AHF CODE) - Q11B 	 medication code  ahf code  q11 b 	 NULL 	 NULL 	 NULL 	 NULL 	 pharmaceutical preparations;factor viii 	 C0013227;C0015506 	 phsu;aapp,bacs,phsu 	 study subject 	 C0681850 	 grup	Medication Patient
phv00095055.v1  	  MEDICATION CODE (AHF CODE) - Q11B 	 medication code  ahf code  q11 b 	 NULL 	 NULL 	 NULL 	 NULL 	 pharmaceutical preparations;factor viii 	 C0013227;C0015506 	 phsu;aapp,bacs,phsu 	 study subject 	 C0681850 	 grup	Medication Patient
phv00007352.v1  	  NONCARDIOVASCULAR MEDICATIONS: OSTEOPOROSIS MEDICATIONS 	 noncardiovascular medications  osteoporosis medications 	 NULL 	 NULL 	 NULL 	 NULL 	 pharmaceutical preparations;osteoporosis;medications:presence or identity:duration of the study:^patient:nominal;medications:-:point in time:^patient:- 	 C0013227;C0029456;C0802604;C2598133 	 phsu;dsyn;clna;clna 	 study subject 	 C0681850 	 grup	Medication Patient;Medical History
phv00079032.v3  	  Take medication for sleep 	 take medication for sleep 	 NULL 	 NULL 	 NULL 	 NULL 	 pharmaceutical preparations;sleep 	 C0013227;C0037313 	 phsu;orgf 	 study subject 	 C0681850 	 grup	Medication Patient;Daily or Recreational Activity
phv00005618.v1  	  MEDICATION USE: ANTI-PARKINSON DRUGS (SINEMET, L-DOPA, SYMMETREL, COGENTIN, ETC.) 	 medication use  anti parkinson drugs  sinemet, ldopa, symmetrel, cogentin, etc 	 NULL 	 NULL 	 NULL 	 NULL 	 pharmaceutical preparations;sinemet;levodopa;symmetrel;cogentin 	 C0013227;C0074559;C0023570;C0026055;C0591275 	 phsu;orch,phsu;aapp,nsba,phsu;orch,phsu;orch,phsu 	 study subject 	 C0681850 	 grup	Medication Patient
phv00095001.v1  	  GET MEDICATIONS INFO LATER?       Q3 	 get medications info later  q3 	 NULL 	 NULL 	 NULL 	 NULL 	 pharmaceutical preparations;medications:presence or identity:duration of the study:^patient:nominal;medications:-:point in time:^patient:- 	 C0013227;C0802604;C2598133 	 phsu;clna;clna 	 study subject 	 C0681850 	 grup	Medication Patient
phv00102090.v1  	  TAKE ANY MEDICATIONS 	 take any medications 	 NULL 	 NULL 	 NULL 	 NULL 	 pharmaceutical preparations;medications:presence or identity:duration of the study:^patient:nominal;medications:-:point in time:^patient:- 	 C0013227;C0802604;C2598133 	 phsu;clna;clna 	 study subject 	 C0681850 	 grup	Medication Patient
phv00087382.v1  	  TOTAL MEDICATIONS 	 total medications 	 NULL 	 NULL 	 NULL 	 NULL 	 pharmaceutical preparations;medications:presence or identity:duration of the study:^patient:nominal;medications:-:point in time:^patient:- 	 C0013227;C0802604;C2598133 	 phsu;clna;clna 	 study subject 	 C0681850 	 grup	Medication Patient
phv00011963.v1  	  E4. Have you ever taken medications for your nerves or any emotional or mental problems? Antidepressants: Wellbutrin. (Participants with European ancestry). DIGS2 	 e4  have you ever taken medications for your nerves or any emotional or mental problems  antidepressants  wellbutrin   participants with european ancestry   digs2 	 Ethnicity 	 ethnic european 	 C0239307 	 popg 	 pharmaceutical preparations;medications:presence or identity:duration of the study:^patient:nominal;medications:-:point in time:^patient:-;emotions;emotional;mental problem;antidepressive agents;wellbutrin;antidepressant measurement 	 C0013227;C0802604;C2598133;C0013987;C0849912;C0848067;C0003289;C0085934;C2698157 	 phsu;clna;clna;menp;fndg;fndg;phsu;orch,phsu;lbpr 	 participant 	 C0679646 	 popg	Demographics Patient;Medication Patient;Lab Tests Patient;Mental or Emotional Finding;Medical History
phv00011965.v1  	  E4. Have you ever taken medications for your nerves or any emotional or mental problems? MAOI's:  Marplan. (Participants with European ancestry). DIGS2 	 e4  have you ever taken medications for your nerves or any emotional or mental problems  monoamine oxidase inhibitor s  marplan   participants with european ancestry   digs2 	 Ethnicity 	 ethnic european 	 C0239307 	 popg 	 pharmaceutical preparations;medications:presence or identity:duration of the study:^patient:nominal;medications:-:point in time:^patient:-;emotions;emotional;mental problem;monoamine oxidase inhibitors;marplan 	 C0013227;C0802604;C2598133;C0013987;C0849912;C0848067;C0026457;C0591755 	 phsu;clna;clna;menp;fndg;fndg;phsu;orch,phsu 	 participant 	 C0679646 	 popg	Demographics Patient;Medication Patient;Mental or Emotional Finding;Medical History
phv00066848.v5  	  Description/Label for chemical subgroup - fourth drug in compound 	 description label for chemical subgroup fourth drug in compound 	 NULL 	 NULL 	 NULL 	 NULL 	 pharmaceutical preparations;pharmacologic substance 	 C0013227;C1254351 	 phsu;phsu 	 study subject 	 C0681850 	 grup	Medication Patient
phv00012668.v1  	  J22. Did you ever need larger amounts of (drug) to get an effect, or find that you could no longer get high on the amount you used to use? INTERVIEWER: code YES if at least 50% more use. C SED. (Participants with European ancestry). DIGS2 	 j22   did you ever need larger amounts of  drug  to get an effect, or find that you could no longer get high on the amount you used to use  interviewer  code yes if at least 50% more use  c sed   participants with european ancestry   digs2 	 Ethnicity 	 ethnic european 	 C0239307 	 popg 	 pharmaceutical preparations;pharmacologic substance;finding;used by 	 C0013227;C1254351;C0243095;C1273517 	 phsu;phsu;fndg;fndg 	 participant 	 C0679646 	 popg	Demographics Patient;Medication Patient;Medical History
phv00012775.v1  	  J32a. While using (drug), did you ever have any psychological problems start or get worse, such as feeling depressed, feeling paranoid, trouble thinking clearly, hearing, smelling, or seeing things, or feeling jumpy? IF YES:) Specify which problems, read appropriate sub questions to confirm response and code. Specify. (Participants with European ancestry). DIGS2 	 j32 a  while using  drug , did you ever have any psychological problems start or get worse, such as feeling depressed, feeling paranoid, trouble thinking clearly, hearing, smelling, or seeing things, or feeling jumpy  if yes   specify which problems, read appropriate sub questions to confirm response and code  specify   participants with european ancestry   digs2 	 Ethnicity 	 ethnic european 	 C0239307 	 popg 	 pharmaceutical preparations;pharmacologic substance;mental problem;deterioration of status;emotions;feelings;depressed mood;thinking, function;thinking and speaking disturbances;hearing;hearing examination finding;smell perception;hallucinations, visual;jumpy;reading (activity);questioning;disease response;response (communication) 	 C0013227;C1254351;C0848067;C1279889;C0013987;C1527305;C0344315;C0039869;C0233629;C0018767;C1455844;C0037361;C0233763;C0860604;C0034754;C0876928;C1704632;C2911692 	 phsu;phsu;fndg;fndg;menp;menp;fndg;menp;mobd;phsf;fndg;orgf;sosy;fndg;dora;menp;fndg;menp 	 participant 	 C0679646 	 popg	Demographics Patient;Medication Patient;Mental or Emotional Finding;Daily or Recreational Activity
phv00012741.v1  	  J28. Did using (drug) cause you to have any other physical health problems (other than withdrawal)? B STIM. (Participants with European ancestry). DIGS2 	 j28   did using  drug  cause you to have any other physical health problems  other than withdrawal   b stim   participants with european ancestry   digs2 	 Ethnicity 	 ethnic european 	 C0239307 	 popg 	 pharmaceutical preparations;pharmacologic substance;physical health problems;withdrawal (dysfunction) 	 C0013227;C1254351;C1446390;C2825032 	 phsu;phsu;fndg;mobd 	 participant 	 C0679646 	 popg	Demographics Patient;Medication Patient;Medical History
phv00011723.v1  	  B5. If yes to B5, specify medication, dosage and duration (Med 4 R's response). (Participants with European ancestry). DIGS2 	 b5  if yes to b5, specify medication, dosage and duration  med 4 r s response    participants with european ancestry   digs2 	 Ethnicity 	 ethnic european 	 C0239307 	 popg 	 pharmaceutical preparations;duration;disease response;response (communication);r prime 	 C0013227;C2926735;C1704632;C2911692;C2603358 	 phsu;phsu;fndg;menp;clna 	 participant 	 C0679646 	 popg	Demographics Patient;Medication Patient;Mental or Emotional Finding
phv00169349.v1  	  Emphysema: received medical treatment or used medications/inhaler 	 emphysema  received medical treatment or used medications inhaler 	 NULL 	 NULL 	 NULL 	 NULL 	 pathological accumulation of air in tissues;pulmonary emphysema;therapeutic procedure;administration procedure;medication use 	 C0013990;C0034067;C0087111;C1533734;C0240320 	 patf;dsyn;topp;topp;fndg 	 study subject 	 C0681850 	 grup	Medication Patient;Therapeutic or Preventive Procedure;Medical History
phv00107253.v1  	  TOOK ESTROGEN IN THE PAST 	 took estrogen in the past 	 NULL 	 NULL 	 NULL 	 NULL 	 estrogens 	 C0014939 	 horm,phsu,strd 	 study subject 	 C0681850 	 grup	Medication Patient
phv00108754.v1  	  SPECIFY OTHER REASONS FOR TAKING ESTROGEN 	 specify other reasons for taking estrogen 	 NULL 	 NULL 	 NULL 	 NULL 	 estrogens 	 C0014939 	 horm,phsu,strd 	 study subject 	 C0681850 	 grup	Medication Patient
phv00108114.v1  	  DAYS PER MONTH TAKE ESTROGEN 	 days per month take estrogen 	 NULL 	 NULL 	 NULL 	 NULL 	 estrogens 	 C0014939 	 horm,phsu,strd 	 study subject 	 C0681850 	 grup	Medication Patient
phv00109716.v1  	  Estrogens,  excluding vaginal creams 	 estrogens, excluding vaginal creams 	 NULL 	 NULL 	 NULL 	 NULL 	 estrogens 	 C0014939 	 horm,phsu,strd 	 study subject 	 C0681850 	 grup	Medication Patient
phv00104934.v1  	  YEAR STOPPED TAKING ESTROGEN 	 year stopped taking estrogen 	 NULL 	 NULL 	 NULL 	 NULL 	 estrogens 	 C0014939 	 horm,phsu,strd 	 study subject 	 C0681850 	 grup	Medication Patient
phv00079644.v3  	  Estrogen pill past year 	 estrogen pill past year 	 NULL 	 NULL 	 NULL 	 NULL 	 estrogens 	 C0014939 	 horm,phsu,strd 	 study subject 	 C0681850 	 grup	Medication Patient
phv00108124.v1  	  DAYS PER MONTH TOOK ESTROGEN 	 days per month took estrogen 	 NULL 	 NULL 	 NULL 	 NULL 	 estrogens 	 C0014939 	 horm,phsu,strd 	 study subject 	 C0681850 	 grup	Medication Patient
phv00108130.v1  	  TOOK ESTROGEN TO PREVENT OTHER SYMPTOMS 	 took estrogen to prevent other symptoms 	 NULL 	 NULL 	 NULL 	 NULL 	 estrogens;prevent (product);symptoms 	 C0014939;C0309872;C1457887 	 horm,phsu,strd;phsu;sosy 	 study subject 	 C0681850 	 grup	Medication Patient;Medical History
phv00078016.v3  	  Did you use an estrogen patch? 	 did you use an estrogen patch 	 NULL 	 NULL 	 NULL 	 NULL 	 estrogens;plaque (lesion) 	 C0014939;C0332461 	 horm,phsu,strd;fndg 	 study subject 	 C0681850 	 grup	Medication Patient
phv00089316.v1  	  Estrogen - Exam 18 	 estrogen exam 18 	 NULL 	 NULL 	 NULL 	 NULL 	 estrogens;medical examination 	 C0014939;C0582103 	 horm,phsu,strd;hlca 	 study subject 	 C0681850 	 grup	Medication Patient
phv00077852.v3  	  Estrogen pill dose per day 	 estrogen pill dose per day 	 NULL 	 NULL 	 NULL 	 NULL 	 estrogens;dose number:number:point in time:^patient:quantitative 	 C0014939;C1114758 	 horm,phsu,strd;clna 	 study subject 	 C0681850 	 grup	Medication Patient
phv00078020.v3  	  Estrogen shots 	 estrogen shots 	 NULL 	 NULL 	 NULL 	 NULL 	 estrogens;childhood immunization 	 C0014939;C1456647 	 horm,phsu,strd;topp 	 study subject 	 C0681850 	 grup	Medication Patient;Therapeutic or Preventive Procedure
phv00077854.v3  	  Months took estrogen shots 	 months took estrogen shots 	 NULL 	 NULL 	 NULL 	 NULL 	 estrogens;childhood immunization 	 C0014939;C1456647 	 horm,phsu,strd;topp 	 study subject 	 C0681850 	 grup	Medication Patient;Therapeutic or Preventive Procedure
phv00065866.v1  	  O6a. Female/reproductive: now uses oral contraceptives 	 o6 a  female reproductive  now uses oral contraceptives 	 NULL 	 NULL 	 NULL 	 NULL 	 female;reproduction;used by;contraceptives, oral;oral contraceptives - consent type 	 C0015780;C0035150;C1273517;C0009905;C1548892 	 fndg;orgf;fndg;phsu;hlca 	 study subject 	 C0681850 	 grup	Medication Patient;Medical History
phv00006929.v1  	  FEMALE HORMONE REPLACEMENT: DOSE/DAY OF PROGESTIN 	 female hormone replacement  dose day of progestin 	 NULL 	 NULL 	 NULL 	 NULL 	 female;hormone replacement therapy;dose number:number:point in time:^patient:quantitative;progestins 	 C0015780;C0282402;C1114758;C0033306 	 fndg;topp;clna;horm,phsu,strd 	 study subject 	 C0681850 	 grup	Medication Patient;Therapeutic or Preventive Procedure;Medical History
phv00007363.v1  	  FEMALE HORMONE REPLACEMENT: DOSE/DAY OF PREMARIN CONJUGATED ESTROGENS, OR OTHER ORAL ESTROGEN 	 female hormone replacement  dose day of premarin conjugated estrogens, or other oral estrogen 	 NULL 	 NULL 	 NULL 	 NULL 	 female;hormone replacement therapy;dose number:number:point in time:^patient:quantitative;premarin;estrogens, conjugated (usp);estrogens 	 C0015780;C0282402;C1114758;C0699710;C0014938;C0014939 	 fndg;topp;clna;horm,phsu,strd;horm,phsu,strd;horm,phsu,strd 	 study subject 	 C0681850 	 grup	Medication Patient;Therapeutic or Preventive Procedure;Medical History
phv00158213.v1  	  FFQ: TAKE IODINE SUPPLEMENT 	 food frequency questionnaire  take iodine supplement 	 NULL 	 NULL 	 NULL 	 NULL 	 food;dietary supplements;iodine;iodine, homeopathic preparation 	 C0016452;C0242295;C0021968;C0885449 	 food;food;elii,phsu;phsu 	 study subject 	 C0681850 	 grup	Medication Patient;Eating or Nutritional Finding
phv00157390.v1  	  FFQ: MULTIVITAMINS BRAND 	 food frequency questionnaire  multivitamins brand 	 NULL 	 NULL 	 NULL 	 NULL 	 food;multivitamin preparation;3-bromoacetoxyandrostan-17-one 	 C0016452;C0301532;C0645690 	 food;orch,phsu,vita;phsu,strd 	 study subject 	 C0681850 	 grup	Medication Patient;Eating or Nutritional Finding
phv00069876.v2  	  FFQ: TAKE ZINC SUPPLEMENT 	 food frequency questionnaire  take zinc supplement 	 NULL 	 NULL 	 NULL 	 NULL 	 food;zinc supplement 	 C0016452;C1268859 	 food;inch,phsu 	 study subject 	 C0681850 	 grup	Medication Patient;Eating or Nutritional Finding
phv00053892.v2  	  YEARS TAKING NITROGLYCERIN (ALL PARTICIPANTS) 	 years taking nitroglycerin  all participants 	 NULL 	 NULL 	 NULL 	 NULL 	 nitroglycerin;glonoine, nitroglycerine, homeopathic preparation 	 C0017887;C0885378 	 orch,phsu;orch,phsu 	 participant 	 C0679646 	 popg	Medication Patient
phv00126671.v1  	  SFFQ: glycine (gm) 	 sffq  glycine  gm 	 NULL 	 NULL 	 NULL 	 NULL 	 glycine 	 C0017890 	 aapp,bacs,phsu 	 study subject 	 C0681850 	 grup	Medication Patient
phv00026199.v1  	  MDI - prescribed change in insulin regimen because of: symptoms of polyuria, polydipsia 	 multiple dose injection prescribed change in insulin regimen because of  symptoms of polyuria, polydipsia 	 NULL 	 NULL 	 NULL 	 NULL 	 injection of therapeutic agent;injection procedure;dose number:number:point in time:^patient:quantitative;prescribed;insulin;treatment protocols;recombinant insulin;symptoms;polyuria;polydipsia 	 C0021485;C1533685;C1114758;C0278329;C0021641;C0040808;C1533581;C1457887;C0032617;C0085602 	 topp;topp;clna;hlca;aapp,horm,phsu;topp;aapp,horm,phsu;sosy;sosy;sosy 	 study subject 	 C0681850 	 grup	Medication Patient;Therapeutic or Preventive Procedure;Medical History
phv00165310.v2  	  BASELINE INSULIN RIA METHOD 	 baseline insulin radioimmunoassay method 	 NULL 	 NULL 	 NULL 	 NULL 	 insulin;radioimmunoassay;recombinant insulin 	 C0021641;C0034580;C1533581 	 aapp,horm,phsu;lbpr;aapp,horm,phsu 	 study subject 	 C0681850 	 grup	Medication Patient;Lab Tests Patient
phv00025787.v1  	  Describe insulin regimen (if different from that described in Question 4) 	 describe insulin regimen  if different from that described in question 4 	 NULL 	 NULL 	 NULL 	 NULL 	 insulin;treatment protocols;recombinant insulin 	 C0021641;C0040808;C1533581 	 aapp,horm,phsu;topp;aapp,horm,phsu 	 study subject 	 C0681850 	 grup	Medication Patient;Therapeutic or Preventive Procedure
phv00029229.v1  	  Change insulin regimen to: units of NPH or lente insulin 	 change insulin regimen to  units of neutral protamine hagedor or lente insulin 	 NULL 	 NULL 	 NULL 	 NULL 	 insulin;treatment protocols;recombinant insulin;protamines;insulin, lente 	 C0021641;C0040808;C1533581;C0033603;C0021659 	 aapp,horm,phsu;topp;aapp,horm,phsu;aapp,bacs,phsu;aapp,horm,phsu 	 study subject 	 C0681850 	 grup	Medication Patient;Therapeutic or Preventive Procedure
phv00122931.v1  	  Meds: Insulin 	 meds  insulin 	 NULL 	 NULL 	 NULL 	 NULL 	 insulin;recombinant insulin 	 C0021641;C1533581 	 aapp,horm,phsu;aapp,horm,phsu 	 study subject 	 C0681850 	 grup	Medication Patient
phv00031671.v1  	  Patient's performance rating: task 1 - draw 9 U of insulin in 0.5cc syringe, trial 2 	 patient s performance rating  task 1 draw 9 u of insulin in 0 5cc syringe, trial 2 	 NULL 	 NULL 	 NULL 	 NULL 	 insulin;recombinant insulin;clinical trials 	 C0021641;C1533581;C0008976 	 aapp,horm,phsu;aapp,horm,phsu;resa 	 study subject 	 C0681850 	 grup	Medication Patient;Research Attributes
phv00029812.v1  	  MDI4  - previous day: units of regular or semi-lente insulin 	 mdi4 previous day  units of regular or semi lente insulin 	 NULL 	 NULL 	 NULL 	 NULL 	 insulin, lente 	 C0021659 	 aapp,horm,phsu 	 study subject 	 C0681850 	 grup	Medication Patient
phv00029810.v1  	  MDI4  - previous day: units of long-acting or ultra-lente insulin 	 mdi4 previous day  units of long acting or ultra lente insulin 	 NULL 	 NULL 	 NULL 	 NULL 	 insulin, lente 	 C0021659 	 aapp,horm,phsu 	 study subject 	 C0681850 	 grup	Medication Patient
phv00050802.v1  	  B5g. Does your health insurance provide coverage for: glucose tablets 	 b5 gram  does your health insurance provide coverage for  glucose tablets 	 NULL 	 NULL 	 NULL 	 NULL 	 health insurance;provide (product);glucose;plasma glucose measurement 	 C0021682;C0359589;C0017725;C0202042 	 hlca;food;bacs,carb,phsu;lbpr 	 study subject 	 C0681850 	 grup	Medication Patient;Lab Tests Patient;Eating or Nutritional Finding
phv00161755.v1  	  Isoleucine 	 isoleucine 	 NULL 	 NULL 	 NULL 	 NULL 	 isoleucine 	 C0022192 	 aapp,bacs,phsu 	 study subject 	 C0681850 	 grup	Medication Patient
phv00007731.v3  	  MENOPAUSE: EVER TAKEN PREMARIN 	 menopause  ever taken premarin 	 NULL 	 NULL 	 NULL 	 NULL 	 menopause;premarin 	 C0025320;C0699710 	 phsf;horm,phsu,strd 	 study subject 	 C0681850 	 grup	Medication Patient;Medical History
phv00166791.v2  	  Methionine 	 methionine 	 NULL 	 NULL 	 NULL 	 NULL 	 methionine 	 C0025646 	 aapp,bacs,phsu 	 study subject 	 C0681850 	 grup	Medication Patient
phv00086053.v2  	  IMMEDIATE-RELEASE NIFEDIPINE 	 immediate release nifedipine 	 NULL 	 NULL 	 NULL 	 NULL 	 nifedipine 	 C0028066 	 orch,phsu 	 study subject 	 C0681850 	 grup	Medication Patient
phv00123789.v1  	  Nitric Oxide: Ambient Air 	 nitric oxide  ambient air 	 NULL 	 NULL 	 NULL 	 NULL 	 nitric oxide 	 C0028128 	 bacs,inch,phsu 	 study subject 	 C0681850 	 grup	Medication Patient
phv00126381.v1  	  LFFQ: MUFA 18:1 (oleic acid) (gm) 	 lffq  mufa 18 1  oleic acid   gm 	 NULL 	 NULL 	 NULL 	 NULL 	 oleic acid 	 C0028928 	 bacs,lipd,phsu 	 study subject 	 C0681850 	 grup	Medication Patient
phv00018414.v1  	  J39. Opiates.  (Participants with European ancestry). DIGS4 	 j39   opiates   participants with european ancestry   diagnostic interview for genetic studies 	 Ethnicity 	 ethnic european 	 C0239307 	 popg 	 opioid abuse;opiate assay;opiates;diagnosis;genetic study 	 C0029095;C0242401;C0376196;C0011900;C2827447 	 mobd;lbpr;hops,phsu;fndg;resa 	 participant 	 C0679646 	 popg	Demographics Patient;Medication Patient;Lab Tests Patient;Substance Use History;Research Attributes;Medical History
phv00018419.v1  	  J40. Opiates.  (Participants with European ancestry). DIGS4 	 j40   opiates   participants with european ancestry   diagnostic interview for genetic studies 	 Ethnicity 	 ethnic european 	 C0239307 	 popg 	 opioid abuse;opiate assay;opiates;diagnosis;genetic study 	 C0029095;C0242401;C0376196;C0011900;C2827447 	 mobd;lbpr;hops,phsu;fndg;resa 	 participant 	 C0679646 	 popg	Demographics Patient;Medication Patient;Lab Tests Patient;Substance Use History;Research Attributes;Medical History
phv00018409.v1  	  J38. Opiates.  (Participants with European ancestry). DIGS4 	 j38   opiates   participants with european ancestry   diagnostic interview for genetic studies 	 Ethnicity 	 ethnic european 	 C0239307 	 popg 	 opioid abuse;opiate assay;opiates;diagnosis;genetic study 	 C0029095;C0242401;C0376196;C0011900;C2827447 	 mobd;lbpr;hops,phsu;fndg;resa 	 participant 	 C0679646 	 popg	Demographics Patient;Medication Patient;Lab Tests Patient;Substance Use History;Research Attributes;Medical History
phv00052792.v1  	  J47 Opiates, (African American participants). DIGS4 	 j47  opiates,  african american participants   diagnostic interview for genetic studies 	 Race 	 african american 	 C0085756 	 popg 	 opioid abuse;opiate assay;opiates;diagnosis;genetic study 	 C0029095;C0242401;C0376196;C0011900;C2827447 	 mobd;lbpr;hops,phsu;fndg;resa 	 participant 	 C0679646 	 popg	Demographics Patient;Medication Patient;Lab Tests Patient;Substance Use History;Research Attributes;Medical History
phv00052746.v1  	  J39 Opiates, (African American participants). DIGS4 	 j39  opiates,  african american participants   diagnostic interview for genetic studies 	 Race 	 african american 	 C0085756 	 popg 	 opioid abuse;opiate assay;opiates;diagnosis;genetic study 	 C0029095;C0242401;C0376196;C0011900;C2827447 	 mobd;lbpr;hops,phsu;fndg;resa 	 participant 	 C0679646 	 popg	Demographics Patient;Medication Patient;Lab Tests Patient;Substance Use History;Research Attributes;Medical History
phv00109022.v1  	  Slow-release nifedipine 	 slow release nifedipine 	 NULL 	 NULL 	 NULL 	 NULL 	 patient discharge;nifedipine;discharge (release);release (procedure) 	 C0030685;C0028066;C0680255;C1963578 	 hlca;orch,phsu;hlca;topp 	 study subject 	 C0681850 	 grup	Medication Patient;Therapeutic or Preventive Procedure
phv00087377.v1  	  SLOW-RELEASE VERAPAMIL 	 slow release verapamil 	 NULL 	 NULL 	 NULL 	 NULL 	 patient discharge;verapamil;discharge (release);release (procedure) 	 C0030685;C0042523;C0680255;C1963578 	 hlca;orch,phsu;hlca;topp 	 study subject 	 C0681850 	 grup	Medication Patient;Therapeutic or Preventive Procedure
phv00107434.v1  	  Slow-release verapamil 	 slow release verapamil 	 NULL 	 NULL 	 NULL 	 NULL 	 patient discharge;verapamil;discharge (release);release (procedure) 	 C0030685;C0042523;C0680255;C1963578 	 hlca;orch,phsu;hlca;topp 	 study subject 	 C0681850 	 grup	Medication Patient;Therapeutic or Preventive Procedure
phv00166859.v2  	  Phosphatidylcholine (carbon:double bond = 36:3) 	 phosphatidylcholine  carbon double bond = 36 3 	 NULL 	 NULL 	 NULL 	 NULL 	 lecithin;phosphatidylcholines 	 C0031617;C1959616 	 bacs,lipd,phsu;bacs,lipd,phsu 	 study subject 	 C0681850 	 grup	Medication Patient
phv00071067.v2  	  Number of months from Baseline to first prednisone burst.  This is calculated by dividing the number of days between Baseline and the first prednisone burst by 30.25. 	 number of months from baseline to first prednisone burst  this is calculated by dividing the number of days between baseline and the first prednisone burst by 30 25 	 NULL 	 NULL 	 NULL 	 NULL 	 prednisone;calculated (procedure) 	 C0032952;C1443182 	 horm,phsu,strd;lbpr 	 study subject 	 C0681850 	 grup	Medication Patient;Lab Tests Patient
phv00109746.v1  	  Probucol 	 probucol 	 NULL 	 NULL 	 NULL 	 NULL 	 probucol 	 C0033215 	 orch,phsu 	 study subject 	 C0681850 	 grup	Medication Patient
phv00085385.v2  	  PROGESTINS 	 progestins 	 NULL 	 NULL 	 NULL 	 NULL 	 progestins 	 C0033306 	 horm,phsu,strd 	 study subject 	 C0681850 	 grup	Medication Patient
phv00056983.v1  	  Progestins 	 progestins 	 NULL 	 NULL 	 NULL 	 NULL 	 progestins 	 C0033306 	 horm,phsu,strd 	 study subject 	 C0681850 	 grup	Medication Patient
phv00106334.v1  	  YEARS TOOK PROGESTIN IN PAST 	 years took progestin in past 	 NULL 	 NULL 	 NULL 	 NULL 	 progestins 	 C0033306 	 horm,phsu,strd 	 study subject 	 C0681850 	 grup	Medication Patient
phv00108755.v1  	  CURRENTLY TAKING PROGESTIN 	 currently taking progestin 	 NULL 	 NULL 	 NULL 	 NULL 	 progestins 	 C0033306 	 horm,phsu,strd 	 study subject 	 C0681850 	 grup	Medication Patient
phv00077669.v3  	  Progesterone use last 2 years 	 progesterone use last 2 years 	 NULL 	 NULL 	 NULL 	 NULL 	 progesterone 	 C0033308 	 horm,phsu,strd 	 study subject 	 C0681850 	 grup	Medication Patient
phv00126541.v1  	  RECALL: aspartame 	 recall  aspartame 	 NULL 	 NULL 	 NULL 	 NULL 	 mental recall;aspartame;recall:-:point in time:^patient:- 	 C0034770;C0003999;C2361119 	 menp;aapp,phsu;clna 	 study subject 	 C0681850 	 grup	Medication Patient;Mental or Emotional Finding
phv00126897.v1  	  RECALL: calcium 	 recall  calcium 	 NULL 	 NULL 	 NULL 	 NULL 	 mental recall;calcium;recall:-:point in time:^patient:- 	 C0034770;C0006675;C2361119 	 menp;bacs,elii,phsu;clna 	 study subject 	 C0681850 	 grup	Medication Patient;Mental or Emotional Finding
phv00126526.v1  	  RECALL: leucine 	 recall  leucine 	 NULL 	 NULL 	 NULL 	 NULL 	 mental recall;leucine;recall:-:point in time:^patient:- 	 C0034770;C0023401;C2361119 	 menp;aapp,bacs,phsu;clna 	 study subject 	 C0681850 	 grup	Medication Patient;Mental or Emotional Finding
phv00126973.v1  	  RECALL: vitamin E (International Units) 	 recall  vitamin e  international units 	 NULL 	 NULL 	 NULL 	 NULL 	 mental recall;vitamin e;recall:-:point in time:^patient:- 	 C0034770;C0042874;C2361119 	 menp;lipd,phsu,vita;clna 	 study subject 	 C0681850 	 grup	Medication Patient;Mental or Emotional Finding;Eating or Nutritional Finding
phv00126893.v1  	  RECALL: pantothenic acid 	 recall  pantothenic acid 	 NULL 	 NULL 	 NULL 	 NULL 	 mental recall;recall:-:point in time:^patient:-;pantothenic acid;blood pantothenic acid analysis;vitamin b5 measurement 	 C0034770;C2361119;C0030342;C0696237;C2700255 	 menp;clna;orch,phsu,vita;lbpr;lbpr 	 study subject 	 C0681850 	 grup	Medication Patient;Lab Tests Patient;Mental or Emotional Finding
phv00126966.v1  	  RECALL: synthetic folate 	 recall  synthetic folate 	 NULL 	 NULL 	 NULL 	 NULL 	 mental recall;recall:-:point in time:^patient:-;folate 	 C0034770;C2361119;C0178638 	 menp;clna;orch,phsu,vita 	 study subject 	 C0681850 	 grup	Medication Patient;Mental or Emotional Finding
phv00052801.v1  	  J48 Sedatives, (African American participants). DIGS4 	 j48  sedatives,  african american participants   diagnostic interview for genetic studies 	 Race 	 african american 	 C0085756 	 popg 	 sedatives;diagnosis;genetic study 	 C0036557;C0011900;C2827447 	 phsu;fndg;resa 	 participant 	 C0679646 	 popg	Demographics Patient;Medication Patient;Research Attributes
phv00052811.v1  	  J49 Sedatives, (African American participants). DIGS4 	 j49  sedatives,  african american participants   diagnostic interview for genetic studies 	 Race 	 african american 	 C0085756 	 popg 	 sedatives;diagnosis;genetic study 	 C0036557;C0011900;C2827447 	 phsu;fndg;resa 	 participant 	 C0679646 	 popg	Demographics Patient;Medication Patient;Research Attributes
phv00168306.v1  	  Prior to your recent stroke, did you ever regularly take multi-vitamins?  (DSF)  Aside from the VISP vitamin, have you regularly taken multi-vitamins during the past year? (FDS) 	 prior to your recent stroke, did you ever regularly take multi vitamins   dsf  aside from the visp vitamin, have you regularly taken multi vitamins during the past year   fds 	 NULL 	 NULL 	 NULL 	 NULL 	 cerebrovascular accident;vitamins 	 C0038454;C0042890 	 dsyn;orch,phsu,vita 	 study subject 	 C0681850 	 grup	Medication Patient;Eating or Nutritional Finding
phv00083148.v1  	  SYMPATHOMIMETICS, ORAL AND INHALED 	 sympathomimetics, oral and inhaled 	 NULL 	 NULL 	 NULL 	 NULL 	 sympathomimetics;inspiration function 	 C0039052;C0004048 	 phsu;orgf 	 study subject 	 C0681850 	 grup	Medication Patient;Medical History
phv00087368.v1  	  SYMPATHOMIMETICS, ORAL AND INHALED 	 sympathomimetics, oral and inhaled 	 NULL 	 NULL 	 NULL 	 NULL 	 sympathomimetics;inspiration function 	 C0039052;C0004048 	 phsu;orgf 	 study subject 	 C0681850 	 grup	Medication Patient;Medical History
phv00066841.v5  	  Description/Label for therapeutic subgroup - third drug in compound 	 description label for therapeutic subgroup third drug in compound 	 NULL 	 NULL 	 NULL 	 NULL 	 the science and art of healing;pharmaceutical preparations;pharmacologic substance 	 C0039796;C0013227;C1254351 	 topp;phsu;phsu 	 study subject 	 C0681850 	 grup	Medication Patient;Therapeutic or Preventive Procedure
phv00126395.v1  	  LFFQ: threonine (gm) 	 lffq  threonine  gm 	 NULL 	 NULL 	 NULL 	 NULL 	 threonine 	 C0040005 	 aapp,bacs,phsu 	 study subject 	 C0681850 	 grup	Medication Patient
phv00072913.v1  	  Tsh (Thyroid stimulating hormone) - Milli-International-Units (MIU) 	 tsh  thyroid stimulating hormone  milli international units  milli-international unit 	 NULL 	 NULL 	 NULL 	 NULL 	 thyrotropin;blood thyroid stimulating hormone analysis;recombinant thyroid-stimulating hormone 	 C0040160;C0696098;C1535531 	 aapp,horm,phsu;lbpr;aapp,horm,phsu 	 study subject 	 C0681850 	 grup	Medication Patient;Lab Tests Patient
phv00053882.v2  	  YEARS TAKING TRIAMTERENE (ALL PARTICIPANTS) 	 years taking triamterene  all participants 	 NULL 	 NULL 	 NULL 	 NULL 	 triamterene 	 C0040869 	 orch,phsu 	 participant 	 C0679646 	 popg	Medication Patient
phv00161764.v1  	  Tyrosine 	 tyrosine 	 NULL 	 NULL 	 NULL 	 NULL 	 tyrosine 	 C0041485 	 aapp,bacs,phsu 	 study subject 	 C0681850 	 grup	Medication Patient
phv00166798.v2  	  Valine 	 valine 	 NULL 	 NULL 	 NULL 	 NULL 	 valine 	 C0042285 	 aapp,bacs,phsu 	 study subject 	 C0681850 	 grup	Medication Patient
phv00098253.v1  	  VIT E:UNITS                         Q5E 	 vit e units q5 e 	 NULL 	 NULL 	 NULL 	 NULL 	 vitamin e 	 C0042874 	 lipd,phsu,vita 	 study subject 	 C0681850 	 grup	Medication Patient
phv00098385.v1  	  Vitamin E without vitamin pills mg 	 vitamin e without vitamin pills magnesium 	 NULL 	 NULL 	 NULL 	 NULL 	 vitamin e;vitamins 	 C0042874;C0042890 	 lipd,phsu,vita;orch,phsu,vita 	 study subject 	 C0681850 	 grup	Medication Patient;Eating or Nutritional Finding
phv00119328.v2  	  FREQ (DAY/WEEK/MONTH) TAKEN (ZINC). Q 4 	 freq  day week month  taken  zinc   q 4 	 NULL 	 NULL 	 NULL 	 NULL 	 zinc 	 C0043481 	 bacs,elii,phsu 	 study subject 	 C0681850 	 grup	Medication Patient
phv00098302.v1  	  ZINC :DOSE PER PILL                 QDE 	 zinc  dose per pill qde 	 NULL 	 NULL 	 NULL 	 NULL 	 zinc;dose number:number:point in time:^patient:quantitative 	 C0043481;C1114758 	 bacs,elii,phsu;clna 	 study subject 	 C0681850 	 grup	Medication Patient
phv00086941.v2  	  AMLODIPINE 	 amlodipine 	 NULL 	 NULL 	 NULL 	 NULL 	 amlodipine 	 C0051696 	 orch,phsu 	 study subject 	 C0681850 	 grup	Medication Patient
phv00085335.v2  	  AMLODIPINE 	 amlodipine 	 NULL 	 NULL 	 NULL 	 NULL 	 amlodipine 	 C0051696 	 orch,phsu 	 study subject 	 C0681850 	 grup	Medication Patient
phv00105021.v1  	  Amlodipine 	 amlodipine 	 NULL 	 NULL 	 NULL 	 NULL 	 amlodipine 	 C0051696 	 orch,phsu 	 study subject 	 C0681850 	 grup	Medication Patient
phv00156518.v2  	  Dietary Biochanin A (mg) 	 dietary biochanin a  magnesium 	 NULL 	 NULL 	 NULL 	 NULL 	 biochanin a 	 C0053622 	 orch,phsu 	 study subject 	 C0681850 	 grup	Medication Patient
phv00124520.v1  	  Time to start of paroxetine 	 time to start of paroxetine 	 NULL 	 NULL 	 NULL 	 NULL 	 paroxetine 	 C0070122 	 orch,phsu 	 study subject 	 C0681850 	 grup	Medication Patient
phv00090842.v1  	  Rifaximin (Xifaxan) 	 rifaximin  xifaxan 	 NULL 	 NULL 	 NULL 	 NULL 	 rifaximin;xifaxan 	 C0073374;C1615611 	 orch,phsu;orch,phsu 	 study subject 	 C0681850 	 grup	Medication Patient
phv00126680.v1  	  SFFQ: sucrose polyester (gm) 	 sffq  sucrose polyester  gm 	 NULL 	 NULL 	 NULL 	 NULL 	 sucrose polyester 	 C0075483 	 carb,lipd,phsu 	 study subject 	 C0681850 	 grup	Medication Patient
phv00120353.v2  	  NUMBER TAKEN (VITAMIN A). Q 2 	 number taken  vitamin a   q 2 	 NULL 	 NULL 	 NULL 	 NULL 	 vitamin a2 	 C0078364 	 orch,phsu,vita 	 study subject 	 C0681850 	 grup	Medication Patient;Eating or Nutritional Finding
phv00029072.v1  	  Standard treatment  - previous day: type of insulin - pork 	 standard treatment previous day  type of insulin pork 	 NULL 	 NULL 	 NULL 	 NULL 	 therapeutic procedure;administration procedure;insulin, pork 	 C0087111;C1533734;C0770206 	 topp;topp;aapp,horm,phsu 	 study subject 	 C0681850 	 grup	Medication Patient;Therapeutic or Preventive Procedure;Daily or Recreational Activity
phv00050038.v1  	  D4a. Treatment of clinical manifestation: given intravenous glucose treatment 	 d4 a  treatment of clinical manifestation  given intravenous glucose treatment 	 NULL 	 NULL 	 NULL 	 NULL 	 therapeutic procedure;administration procedure;clinical treatment;parenteral form glucose 	 C0087111;C1533734;C1516635;C0357164 	 topp;topp;topp;carb,phsu 	 study subject 	 C0681850 	 grup	Medication Patient;Therapeutic or Preventive Procedure
phv00126239.v1  	  PUFA 18:3 (linolenic acid) (g) 	 polyunsaturated fatty acid 18 3  linolenic acid   gram 	 NULL 	 NULL 	 NULL 	 NULL 	 linolenic acid 	 C0125903 	 bacs,lipd,phsu 	 study subject 	 C0681850 	 grup	Medication Patient
phv00015028.v1  	  E6. Serotonin specific reuptke inhibitors (SSRIs. Celexa, (Participants with European ancestry). DIGS3 	 e6  serotonin specific reuptke inhibitors  ssris  celexa,  participants with european ancestry   digs3 	 Ethnicity 	 ethnic european 	 C0239307 	 popg 	 serotonin uptake inhibitors;selective serotonin re-uptake inhibitor;celexa 	 C0162758;C0360105;C0719199 	 phsu;phsu;orch,phsu 	 participant 	 C0679646 	 popg	Demographics Patient;Medication Patient
phv00005584.v1  	  MEDICATION USE: RENIN-ANGIOTENSIN BLOCKING DRUGS (CAPTOPRIL, ENALAPRIL, LISINOPRIL) 	 medication use  renin angiotensin blocking drugs  captopril, enalapril, lisinopril 	 NULL 	 NULL 	 NULL 	 NULL 	 medication use;angiotensins;captopril;chymosin;enalapril;lisinopril 	 C0240320;C0003018;C0006938;C0035100;C0014025;C0065374 	 fndg;aapp,bacs,phsu;aapp,phsu;aapp,enzy,phsu;aapp,phsu;aapp,phsu 	 study subject 	 C0681850 	 grup	Medication Patient
phv00004999.v1  	  MEDICATION USE: ANTICONVULSANTS (DILANTIN, PHENOBARB, TEGRETOL, MYSOLINE, ETC.) 	 medication use  anticonvulsants  dilantin, phenobarb, tegretol, mysoline, etc 	 NULL 	 NULL 	 NULL 	 NULL 	 medication use;anticonvulsants;dilantin;tegretol;mysoline 	 C0240320;C0003286;C0699512;C0700087;C0700016 	 fndg;phsu;orch,phsu;orch,phsu;orch,phsu 	 study subject 	 C0681850 	 grup	Medication Patient
phv00004981.v1  	  MEDICATION USE: INSULIN 	 medication use  insulin 	 NULL 	 NULL 	 NULL 	 NULL 	 medication use;insulin;recombinant insulin;pharmaceutical preparations;insulin used 	 C0240320;C0021641;C1533581;C0013227;C0240016 	 fndg;aapp,horm,phsu;aapp,horm,phsu;phsu;fndg 	 study subject 	 C0681850 	 grup	Medication Patient
phv00006150.v1  	  MEDICATION USE - THYROID EXTRACT (DESSICATED THYROID) 	 medication use thyroid extract  dessicated thyroid 	 NULL 	 NULL 	 NULL 	 NULL 	 medication use;thyroid preparation 	 C0240320;C0279175 	 fndg;horm,orch,phsu 	 study subject 	 C0681850 	 grup	Medication Patient
phv00004992.v1  	  MEDICATION USE: ANTIULCER (TAGAMET, RANITIDINE, PROBANTHINE, H-ION INHIBITORS) 	 medication use  antiulcer  tagamet, ranitidine, probanthine, hion inhibitors 	 NULL 	 NULL 	 NULL 	 NULL 	 medication use;tagamet;ranitidine;probanthine 	 C0240320;C0592157;C0034665;C0728760 	 fndg;orch,phsu;orch,phsu;orch,phsu 	 study subject 	 C0681850 	 grup	Medication Patient
phv00109004.v1  	  Erectile dysfunction drugs 	 erectile dysfunction drugs 	 NULL 	 NULL 	 NULL 	 NULL 	 erectile dysfunction;pharmaceutical preparations;erectile dysfunction adverse event 	 C0242350;C0013227;C1961100 	 dsyn;phsu;fndg 	 study subject 	 C0681850 	 grup	Medication Patient;Medical History
phv00016038.v1  	  J50. Opioids Despite Objection, (Participants with European ancestry). DIGS3 	 j50   opioids despite objection,  participants with european ancestry   digs3 	 Ethnicity 	 ethnic european 	 C0239307 	 popg 	 opioids 	 C0242402 	 hops,phsu 	 participant 	 C0679646 	 popg	Demographics Patient;Medication Patient;Substance Use History
phv00086965.v2  	  ANTICHOLINERGICS + COMBINATION WITH BETA2-AGONIST (121200) 	 anticholinergics + combination with beta2 agonist  121200 	 NULL 	 NULL 	 NULL 	 NULL 	 anticholinergic agents;agonists 	 C0242896;C0243192 	 phsu;phsu 	 study subject 	 C0681850 	 grup	Medication Patient
phv00015111.v1  	  E6. Antimaniac agents Oth Antimanic Agt 1 Spec, (Participants with European ancestry). DIGS3 	 e6  antimaniac agents oth antimanic agt 1 spec,  participants with european ancestry   digs3 	 Ethnicity 	 ethnic european 	 C0239307 	 popg 	 antimanic agents;pharmacologic substance 	 C0242911;C1254351 	 phsu;phsu 	 participant 	 C0679646 	 popg	Demographics Patient;Medication Patient
phv00001251.v1  	  INTERIM HISTORY OF MEDICINE:  ANTIBACTERIAL 	 interim history of medicine  antibacterial 	 NULL 	 NULL 	 NULL 	 NULL 	 medical history;history of previous events;pharmaceutical preparations 	 C0262926;C2004062;C0013227 	 fndg;fndg;phsu 	 study subject 	 C0681850 	 grup	Medication Patient;Medical History
phv00000954.v1  	  INTERIM HISTORY OF DRUGS TAKEN: HYPOCHOLESTEROL, EXAM 7 	 interim history of drugs taken  hypocholesterol, exam 7 	 NULL 	 NULL 	 NULL 	 NULL 	 medical history;history of previous events;pharmaceutical preparations;medical examination 	 C0262926;C2004062;C0013227;C0582103 	 fndg;fndg;phsu;hlca 	 study subject 	 C0681850 	 grup	Medication Patient;Medical History
phv00002220.v1  	  INTERIM HISTORY OF MEDICINE USED: NITRITES 	 interim history of medicine used  nitrites 	 NULL 	 NULL 	 NULL 	 NULL 	 medical history;history of previous events;pharmaceutical preparations;used by 	 C0262926;C2004062;C0013227;C1273517 	 fndg;fndg;phsu;fndg 	 study subject 	 C0681850 	 grup	Medication Patient;Medical History
phv00001820.v1  	  INTERIM HISTORY OF MEDICINE USED: NITRITES 	 interim history of medicine used  nitrites 	 NULL 	 NULL 	 NULL 	 NULL 	 medical history;history of previous events;pharmaceutical preparations;used by 	 C0262926;C2004062;C0013227;C1273517 	 fndg;fndg;phsu;fndg 	 study subject 	 C0681850 	 grup	Medication Patient;Medical History
phv00002951.v1  	  INTERIM HISTORY OF MEDICINE USED: CARDIAC GLYCOSIDES 	 interim history of medicine used  cardiac glycosides 	 NULL 	 NULL 	 NULL 	 NULL 	 medical history;history of previous events;pharmaceutical preparations;used by;cardiac glycosides 	 C0262926;C2004062;C0013227;C1273517;C0007158 	 fndg;fndg;phsu;fndg;carb,phsu 	 study subject 	 C0681850 	 grup	Medication Patient;Medical History
phv00001445.v1  	  INTERIM HISTORY OF MEDICINE USED: HYPOGLYCEMIC AGENTS 	 interim history of medicine used  hypoglycemic agents 	 NULL 	 NULL 	 NULL 	 NULL 	 medical history;history of previous events;pharmaceutical preparations;used by;hypoglycemic agents 	 C0262926;C2004062;C0013227;C1273517;C0020616 	 fndg;fndg;phsu;fndg;phsu 	 study subject 	 C0681850 	 grup	Medication Patient;Medical History
phv00056994.v1  	  Thyroid agents 	 thyroid agents 	 NULL 	 NULL 	 NULL 	 NULL 	 thyroid preparation 	 C0279175 	 horm,orch,phsu 	 study subject 	 C0681850 	 grup	Medication Patient
phv00112705.v2  	  IRON (MG) 	 iron  magnesium 	 NULL 	 NULL 	 NULL 	 NULL 	 iron;ferrum metallicum, homeopathic preparation 	 C0302583;C1166521 	 bacs,elii,phsu;phsu 	 study subject 	 C0681850 	 grup	Medication Patient
phv00008106.v3  	  IRON 	 iron 	 NULL 	 NULL 	 NULL 	 NULL 	 iron;ferrum metallicum, homeopathic preparation 	 C0302583;C1166521 	 bacs,elii,phsu;phsu 	 study subject 	 C0681850 	 grup	Medication Patient
phv00079522.v3  	  Supplemental Potassium, mg 	 supplemental potassium, magnesium 	 NULL 	 NULL 	 NULL 	 NULL 	 potassium supplement 	 C0304475 	 inch,phsu 	 study subject 	 C0681850 	 grup	Medication Patient;Substance Use History
phv00163806.v2  	  Was the Patient Exposed to Hydroxyurea Prior to Procurement? 	 was the patient exposed to hydroxyurea prior to procurement 	 NULL 	 NULL 	 NULL 	 NULL 	 exposure to;hydroxyurea 	 C0332157;C0020402 	 clna;orch,phsu 	 study subject 	 C0681850 	 grup	Medication Patient
phv00055358.v2  	  Loop diuretics 	 loop diuretics 	 NULL 	 NULL 	 NULL 	 NULL 	 loop diuretics 	 C0354100 	 phsu 	 study subject 	 C0681850 	 grup	Medication Patient
phv00107435.v1  	  Oral anticoagulants 	 oral anticoagulants 	 NULL 	 NULL 	 NULL 	 NULL 	 anticoagulants, oral 	 C0354604 	 orch,phsu 	 study subject 	 C0681850 	 grup	Medication Patient
phv00007335.v1  	  ORAL HYPOGLYCEMICS: UNKNOWN 	 oral hypoglycemics  unknown 	 NULL 	 NULL 	 NULL 	 NULL 	 oral hypoglycemic 	 C0359086 	 phsu 	 study subject 	 C0681850 	 grup	Medication Patient
phv00004621.v1  	  ORAL HYPOGLYCEMICS 	 oral hypoglycemics 	 NULL 	 NULL 	 NULL 	 NULL 	 oral hypoglycemic 	 C0359086 	 phsu 	 study subject 	 C0681850 	 grup	Medication Patient
phv00077725.v3  	  Natural/Progest suppositories 	 natural progest suppositories 	 NULL 	 NULL 	 NULL 	 NULL 	 progesterone measurement;progest 	 C0373705;C0893455 	 lbpr;phsu,strd 	 study subject 	 C0681850 	 grup	Medication Patient;Lab Tests Patient
phv00014755.v1  	  B 5. Medication Weeks - 3, (Participants with European ancestry). DIGS3 	 b 5  medication weeks 3,  participants with european ancestry   digs3 	 Ethnicity 	 ethnic european 	 C0239307 	 popg 	 ((5,6-dichloro-2,3,9,9a-tetrahydro-3-oxo-9a-propyl-1h-fluoren-7-yl)oxy)acetic acid;pharmaceutical preparations 	 C0378071;C0013227 	 orch,phsu;phsu 	 participant 	 C0679646 	 popg	Demographics Patient;Medication Patient
phv00158562.v1  	  Medication start period is estimated - coded fields 	 medication start period is estimated coded fields 	 NULL 	 NULL 	 NULL 	 NULL 	 medication commenced 	 C0451613 	 fndg 	 study subject 	 C0681850 	 grup	Medication Patient;Medical History
phv00086027.v2  	  ANTI-PSYCHOTIC MEDICATIONS 	 anti psychotic medications 	 NULL 	 NULL 	 NULL 	 NULL 	 psychotic symptom present;pharmaceutical preparations;medications:presence or identity:duration of the study:^patient:nominal;medications:-:point in time:^patient:- 	 C0459435;C0013227;C0802604;C2598133 	 fndg;phsu;clna;clna 	 study subject 	 C0681850 	 grup	Medication Patient;Medical History
